Medtronic (MDT) Stock Forecast & Price Target

$83.78 -0.09 (-0.11%)

Closing price 07/10/2026 03:59 PM Eastern

Extended Trading

$84.28 +0.50 (+0.60%)

As of 04:27 AM Eastern

Compare

Medtronic - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Moderate Buy

Based on 27 Analyst Ratings

Sell
0

Hold
10

Buy
17

Based on 27 Wall Street analysts who have issued ratings for Medtronic in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 27 analysts, 10 have given a hold rating, and 17 have given a buy rating for MDT.

Consensus Price Target

$98.17
17.18% Upside

According to the 27 analysts' twelve-month price targets for Medtronic, the average price target is $98.17. The highest price target for MDT is $120.00, while the lowest price target for MDT is $78.00. The average price target represents a forecasted upside of 17.18% from the current price of $83.78.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for MDT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Medtronic and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

MDT Analyst Ratings Over Time

Type	Current Forecast 7/13/25 to 7/13/26	1 Month Ago 6/13/25 to 6/13/26	3 Months Ago 4/14/25 to 4/14/26	1 Year Ago 7/13/24 to 7/13/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	2 Strong Buy rating(s)
Buy	17 Buy rating(s)	17 Buy rating(s)	16 Buy rating(s)	7 Buy rating(s)
Hold	10 Hold rating(s)	11 Hold rating(s)	10 Hold rating(s)	11 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$98.17	$99.00	$110.00	$97.47
Forecasted Upside	17.18% Upside	23.58% Upside	24.84% Upside	8.27% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

MDT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

MDT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Medtronic Stock vs. The Competition

Type	Medtronic	Medical Companies	Broader Market
Consensus Rating Score	2.63	2.30	2.52
Consensus Rating	Moderate Buy	Hold	Moderate Buy
Predicted Upside	17.18% Upside	701.52% Upside	13.82% Upside
News Sentiment Rating	Positive News See Recent MDT News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
7/10/2026	TD Cowen 3 of 5 stars	Joshua Jennings Not Rated	Lower Target	Buy	$119.00 ➝ $100.00	+20.72%
7/6/2026	Evercore 3 of 5 stars	Vijay Kumar 3 of 5 stars	Set Target		$105.00	+27.49%
6/17/2026	Needham & Company LLC 4 of 5 stars	Mike Matson 2 of 5 stars	Reiterated Rating	Buy	$101.00	+24.14%
6/16/2026	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matt O'Brien Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Neutral	$85.00	+4.58%
6/5/2026	Rothschild & Co Redburn Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Buy	$111.00 ➝ $106.00	+28.58%
6/4/2026	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lee Hambright Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$112.00 ➝ $97.00	+17.46%
6/4/2026	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Priya Sachdeva Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Neutral	$90.00 ➝ $85.00	+8.86%
6/4/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matthew Taylor Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Hold	$88.00	+12.70%
6/4/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Neutral	$100.00 ➝ $86.00	+4.07%
6/4/2026	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Richard Newitter Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Hold	$95.00 ➝ $86.00	+4.18%
Porter flew 3,300 miles to investigate this system (Ad) Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experiment called Project Prophet - and documented everything on film. Rooted in the laws of physics, this quantitative approach challenges conventional wealth-building wisdom. With 17 years of verified data behind it, Porter calls it unlike anything he has seen in nearly 30 years in the business. Watch the full investigation and decide for yourself
6/4/2026	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Hold	$100.00 ➝ $78.00	-5.51%
6/4/2026	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Roman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Neutral	$84.00 ➝ $83.00	+0.55%
6/4/2026	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Shagun Singh Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform	$118.00	+46.09%
6/4/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Larry Biegelsen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$114.00 ➝ $102.00	+30.63%
6/4/2026	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Kratky Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$117.00 ➝ $104.00	+33.19%
6/4/2026	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Rescott Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Neutral	$93.00 ➝ $85.00	+8.86%
6/3/2026	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ryan Zimmerman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$90.00	+15.26%
6/3/2026	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Rick Wise Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$80.00	+2.45%
6/3/2026	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Anthony Petrone Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Outperform	$120.00 ➝ $100.00	+35.64%
5/21/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Hold (C+) ➝ Hold (C)
4/7/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joanne Wuensch Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$117.00 ➝ $110.00	+27.75%
4/6/2026	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Toung Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$125.00 ➝ $115.00	+32.76%
4/1/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matt Miksic Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$118.00 ➝ $120.00	+39.57%
2/27/2026	Daiwa Securities Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Lower Target	Buy	$117.00 ➝ $115.00	+17.83%
1/30/2026	CICC Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Initiated Coverage	Outperform
1/6/2026	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brandon Vazquez Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
11/19/2025	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Cecilia Furlong Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Overweight	$107.00 ➝ $117.00	+16.20%
6/30/2025	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Polark Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Underperform ➝ Peer Perform
8/21/2024	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Market Perform	$92.00 ➝ $94.00	+10.10%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 04:16 AM ET.

Should I Buy Medtronic Stock? MDT Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Sunday, July 12, 2026. Please send any questions or comments about these Medtronic pros and cons to contact@marketbeat.com.

Medtronic
Bull Case

Here are some ways that investors could benefit from investing in Medtronic plc:

Medtronic plc recently reported earnings per share of $1.55, exceeding analyst expectations, which indicates strong financial performance and potential for growth.
The company achieved a revenue of $9.81 billion for the quarter, surpassing estimates, reflecting robust demand for its medical technology products.
Medtronic plc has a solid return on equity of 14.51%, suggesting effective management and profitability in generating returns for shareholders.
The recent increase in the quarterly dividend to $0.72, up from $0.71, demonstrates the company's commitment to returning value to shareholders, with an annualized yield of approximately 3.5%.
The current stock price is around $85, which may present a favorable entry point for investors looking to capitalize on the company's growth trajectory.

Medtronic
Bear Case

Investors should be bearish about investing in Medtronic plc for these reasons:

The company's earnings per share decreased from $1.62 in the same quarter last year, indicating a potential decline in profitability.
Medtronic plc's net margin of 13.20% may suggest that there are pressures on profitability, which could affect future earnings.
The payout ratio is currently at 77.21%, which indicates that a significant portion of earnings is being distributed as dividends, potentially limiting funds available for reinvestment in growth opportunities.
Analysts predict earnings per share of 5.94 for the current year, which may not meet investor expectations for growth compared to previous performance.
Market conditions and competition in the medical technology sector could pose risks to Medtronic plc's future revenue and profitability, making it a more cautious investment choice.

MDT Forecast - Frequently Asked Questions

According to the research reports of 27 Wall Street equities research analysts, the average twelve-month stock price forecast for Medtronic is $98.17, with a high forecast of $120.00 and a low forecast of $78.00.

27 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Medtronic in the last year. There are currently 10 hold ratings and 17 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MDT shares.

According to analysts, Medtronic's stock has a predicted upside of 17.18% based on their 12-month stock forecasts.

Over the previous 90 days, Medtronic's stock had 3 upgrades and 2 downgrades by analysts.

Medtronic has been rated by research analysts at BTIG Research, Deutsche Bank Aktiengesellschaft, Evercore, Jefferies Financial Group, JPMorgan Chase & Co., Leerink Partners, Mizuho, Needham & Company LLC, Piper Sandler, Robert W. Baird, Rothschild & Co Redburn, Royal Bank Of Canada, Sanford C. Bernstein, Stifel Nicolaus, TD Cowen, The Goldman Sachs Group, Truist Financial, UBS Group, Weiss Ratings, and Wells Fargo & Company in the past 90 days.

Analysts like Medtronic more than other "medical" companies. The consensus rating for Medtronic is Moderate Buy while the average consensus rating for "medical" companies is Hold. Learn more on how MDT compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Medtronic Recommendations

This page (NYSE:MDT) was last updated on 7/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Medtronic (MDT) Stock Forecast & Price Target

Medtronic - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

MDT Analyst Ratings Over Time

MDT Analyst Recommendations By Month

MDT Price Targets by Month

Medtronic Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Medtronic Stock? MDT Pros and Cons Explained

Medtronic
Bull Case

Medtronic
Bear Case

MDT Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Medtronic Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Medtronic (MDT) Stock Forecast & Price Target

Medtronic - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

MDT Analyst Ratings Over Time

MDT Analyst Recommendations By Month

MDT Price Targets by Month

Medtronic Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

Should I Buy Medtronic Stock? MDT Pros and Cons Explained

Medtronic Bull Case

Medtronic Bear Case

MDT Forecast - Frequently Asked Questions

What is Medtronic's forecast for 2026?

Should I buy or sell Medtronic stock right now?

Does Medtronic's stock price have much upside?

Has Medtronic been upgraded or downgraded by Wall Street analysts recently?

What analysts cover Medtronic?

Do Wall Street analysts like Medtronic more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Medtronic Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

Medtronic
Bull Case

Medtronic
Bear Case